GOSH researchers receive UCL Business Award

23 Jun 2017, 12:57 p.m.

Professors Bobby Gasper and Adrian Thrasher, both members of the BRC senior management team, have been awarded the UCL Business Award, in recognition of their work on the spin-out company Orchard Therapeutics.

Orchard is a biotechnology company focused on the development and commercialization of gene therapy medicines for children with rare diseases. It was launched in May 2016 with support from UCL Business and a £21 million investment from F-Prime Capital Partners.

Orchard focusses on restoring normal gene function in immunodeficiencies, metabolic diseases and haematological disorders and builds on GOSH researchers' expertise in stem, cell and gene therapies. Read more.

Professor Gaspar is Deputy Director of the NIHR GOSH BRC and Professor Thrasher is BRC Theme Lead for Gene, Stem and Cellular Therapies.

New treatment for brain tumour approved after over 20 years of research

The first-ever targeted treatment for brain tumours in children has been approved for NHS patients, following decades of research by a Great Ormond Street consultant.

Help pioneer new treatments for millions of people this DNA Day

DNA Day is coming up this Thursday (25 April) and the team behind the DNA, Children + Young People’s Health Resource (D-CYPHR) are encouraging children and young people to contribute to important health research.

New study finds that nasal cells protect against Covid-19 in children

New research shows that children are less likely than adults to develop severe COVID because cells in their nose are better at fighting off the virus.

New plan announced to get more children access to gene therapy treatments

Great Ormond Street Hospital (GOSH) has announced plans to revolutionise how children living with a rare disease can gain access to life-changing treatments.